Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AAM, PhRMA Renew Rivalry In Hatch-Waxman Public Comments

Nov 22 2017

• By Michael Cipriano

Related Content

Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

Jul 28 2017

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

Jul 19 2017

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Apr 30 2017

Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive

Jul 20 2017

Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain

Aug 19 2016

Additional Topics

United States Generic Drugs FDA Regulation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window